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Introduction: Indacaterol is a novel inhaled once-daily long-acting beta2-agonist (LABA) for
the maintenance treatment of COPD that has been compared to existing inhaled monothera-
pies on a number of symptomatic endpoints in clinical studies. With constrained healthcare
budgets, the objective of this analysis was to evaluate the cost-effectiveness of indacaterol
150 mg, the approved starting dose for maintenance therapy, from a German heath service
perspective against the most widely used bronchodilator tiotropium, and the twice-daily LABA,
salmeterol.
Methods: A Markov model was developed with the following main health states: Mild,
Moderate, Severe, and Very Severe COPD, based on pre-bronchodilator FEV1 measures re-
ported in the indacaterol clinical trials, and death. Each disease severity health state had
two associated health states for severe or non-severe exacerbation. The model considered
patients with moderate to severe COPD, with a mean age of 64 years. The base case time
horizon was three years, with discounting set at 3% for costs and benefits. Selected clinical
inputs and health state utilities were derived from indacaterol clinical trials, while costs were
based on publicly available drug prices and tariffs or published sources. Inputs describing
disease progression were based on published data on the rate of FEV1 decline.20 3075 4801; fax: þ44 0 20 3075 4840.
alth.com (Y. Asukai).
1 Elsevier Ltd. All rights reserved.
1636 D. Price et al.Results: Point-estimates show that indacaterol 150 mg is dominant (lower total costs and
better outcomes) against tiotropium and salmeterol. An alternative analysis comparing indaca-
terol 300 mg (maximum dose) against tiotropium, showed an incremental cost-effectiveness
ratio (ICER) of approximately V28,300 per QALY.
Conclusion: Indacaterol is cost-effective compared to tiotropium and salmeterol.
ª 2011 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a progres-
sive disease with irreversible effects on lung function. The
prevalence in Germany was estimated to be 7.83% of the
total population in 2008 and is expected to rise to 11.53% by
2050.1 It is the sixth leading cause of death responsible for
22,328 deaths in Germany in 2008.2
The pulmonary component of COPD is characterised by
airflow limitation that is not fully reversible and patients
experience symptoms such as breathlessness, cough3 and
poor health-related quality-of-life.4 COPD patients are also
susceptible to exacerbations consisting of worsening of
symptoms, which may require a change in medication,
unscheduled health care utilisation or hospital inpatient
stay.5
Current guidelines recommend that patients with
moderate to severe COPD initiate therapy with long-acting
bronchodilators if short-acting bronchodilators are not
providing sufficient symptom relief.3 Indacaterol is a new
once-daily long-acting beta2-agonist (LABA) that has
previously been compared to existing long-acting broncho-
dilators on clinical endpoints in randomised controlled
studies6e10; since healthcare budgets are constrained we
should now evaluate its cost-effectiveness.
Healthcare budgets are increasingly under constraint
and therefore, the economic profile of indacaterol should
be examined from the healthcare system’s perspective as
a potential alternative for COPD patients. This analysis
combined clinical trial data from two long-term trials of
indacaterol6,11 (150 and 300 mg doses) and applied the data
within an economic model to estimate the expected costs
and outcomes associated with indacaterol’s use, compared
to tiotropium and salmeterol. The 150 mg dose is presented
as the base case as this is the standard dose according to
German Summary of Product Characteristics (SmPC).
Patients may be allowed to increase their dose to the
300 mg dose on medical advice, in line with the SmPC, which
suggests there is an additional clinical benefit with a higher
dose with regard to breathlessness, particularly for patients
with severe COPD. Therefore the results of the comparison
of indacaterol 300 mg versus tiotropium have also been
presented. Indacaterol 300 mg was not included in the trial
versus salmeterol and results are therefore not available
from the clinical studies. For the German health care
context, the statutory health insurance (SHI) perspective
was chosen for the model, which does not consider societal
costs such as productivity losses. The SHI is the statutory
health insurance under which approximately 90% of the
German population is covered.
A cost-effectiveness analysis (CEA) evaluates one health
technology against one or more alternative technologies.The marginal cost required to gain one unit of benefit,
represented by the incremental cost-effectiveness ratio
(ICER), is one output of a CEA model used to judge cost-
effectiveness. This is frequently in the form of the cost per
quality-adjusted life year (QALY) gained, as the QALY is
a widely used outcome measure permitting comparisons
across therapeutic areas.12 CEAs employing the QALY are
known as cost-utility analyses (CUA).
An economic evaluation of COPD interventions needs to
capture long-term effects, yet clinical trials for regulatory
purposes tend to be 6 months in duration or less. Therefore
economic modelling techniques are required to explore
long-term effects associated with new interventions.
Objective
This analysis aimed to establish the cost-effectiveness
profile of indacaterol compared to the once-daily long-
acting muscarinic antagonist (LAMA) tiotropium and the
twice-daily long-acting beta2-agonist (LABA) salmeterol, in
patients with moderate to severe COPD, by using economic
modelling techniques from a German healthcare provider
perspective.
Methods
Model structure
A Markov model is an appropriate model structure used to
model diseases of a chronic degenerative nature with
recurring events such as COPD exacerbations. A review of
the literature showed precedents for this type of work.13e18
A Markov model is comprised of discrete health states
that describe the status of a patient. Patients stay in one
health state for the duration of a model cycle, accumu-
lating the costs and benefits associated with that health
state. At the end of a cycle, patients may remain in a state
or move to another state, according to defined transition
probabilities.
This analysis used a Markov model constructed in
Microsoft Excel 2003 (Microsoft, Redmond, Washington)
with four main health states describing the severity of
COPD plus a state for death. For each disease severity
state, two further health states were created for patients
who experienced a severe or non-severe exacerbation, to
give 12 states plus death in total, as shown in Fig. 1. Mirror
states were created for the 12 health states to describe the
disease progression of patients who discontinued therapy.
Cycle lengths were set to three months in order to
capture transition probabilities of patients who may have
initially improved their lung function sufficiently to change
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Figure 1 Model Schematic.
Cost-utility analysis of indacaterol in Germany 1637disease severity state. Clinical trial data show that
improvement in trough FEV1 (Forced Expiratory Volume in
1 s) is recorded over the first 8e16 weeks of treatment, and
trough FEV1 versus placebo after 12 weeks of treatment was
the primary objective of the indacaterol studies.
Discounting was set to 3% per annum for both costs and
outcomes in line with the German recommendations for
health technology assessment.19 The rationale for con-
ducting the analysis over a three-year period was that an
economic evaluation should cover the full period over
which the benefits and costs of an intervention are expec-
ted to be accumulated.20 The relevant clinical trials for
indacaterol extended to 6 months yet it is reasonable to
expect patients to take indacaterol for longer time periods
given that COPD is a life-long, progressive illness. However,
extrapolating 6 month data out to very long time periods
would lead to unacceptable levels of uncertainty in the
analysis. A three-year duration was considered sufficient to
capture costs and benefits while at the same time limiting
the extent of extrapolation. Furthermore, beyond three
years, many patients are likely to increase or change their
maintenance therapy.21Patient population
The patient population of the clinical trials on which this
analysis was based had moderate to severe COPD (classified
by post-bronchodilator FEV1) and a mean age of 63.6 years
(Table 1). The starting distribution in the model reflects the
baseline distribution of each trial among the disease states
of mild, moderate, severe and very severe (i.e. 1.4%,
36.7%, 50.2% and 11.7% respectively for indacaterol versustiotropium and 1.2%, 41.3%, 49.4% and 8.1% respectively
versus salmeterol). Post-bronchodilator measurement of
FEV1 is recommended in COPD guidelines for assessment of
disease severity3 but apart from the screening visit these
measurements were not taken in the indacaterol trials. As
a consequence, and in line with previous economic anal-
yses13,14 we used pre-bronchodilator values. Furthermore,
other key inputs for the model such as utilities and medical
resource use were also available by pre-bronchodilator
measurements. Since pre-bronchodilator values are used
for all comparators the impact on incremental cost-
effectiveness results is minimal. The cut-off points adop-
ted to define severity were the same as the Global Initiative
for Chronic Obstructive Lung Disease (GOLD), taking FEV1
over predicted normal lung function to ascertain
percentage of predicted lung function.
Analysis
A cohort analysis was conducted with the Markov model,
passing 1000 patients through the model to derive the
expected costs and outcomes for each type of intervention.
The results were then used to calculate the ICER. Outcomes
were defined in QALYs.
Sensitivity analyses
Two sensitivity analysis approaches were adopted: Univar-
iate sensitivity analysis (USA) and probabilistic sensitivity
analysis (PSA). USA varies one parameter input at a time, to
examine the impact it has on the final result. This is one
way to ascertain the key drivers of cost-effectiveness in the
Table 1 Patient characteristics in clinical trials used to inform the model.
Trial INHANCE INLIGHT2
Study arms Indacaterol 150 mg Indacaterol 150 mg
Indacaterol 300 mg Salmeterol 50 mg bid
Tiotropium 18 mg
Length of study 26 weeks 26 weeks
n (randomised) 1683 998
Mean age years (sd) 63.6 (9.1) 63.5 (8.81)
Proportion of males (%) 62.8% 74.6%
Duration of COPD years (sd) 6.8 (6.75) 6.5 (5.71)
Mean number of pack years (sd) 49.7 (25.09) 40.2 (17.56)
Smoking habits (%)
Ex-smokers 54.8% 54.3%
Smokers 45.2% 45.7%
1638 D. Price et al.model and to assess the effects of modelling methods and
assumptions such as the duration of the analysis. PSA deals
exclusively with sampling variability in a population, and
varies all input parameters simultaneously using randomly
generated values drawn from a defined distribution. This is
separate from uncertainty in modelling methodology or
assumptions, and allows quantification of the uncertainty
surrounding the result by repeating the analysis several
hundred times, creating a joint probability distribution
around the mean result.Clinical model inputs
Clinical inputs for the model were largely derived from two
key, longer-term trials for indacaterol. The trials were both
multi-centre, placebo-controlled, randomized studies with
active controls.6,7 The INLIGHT-2 trial was double-blind for
the placebo and salmeterol arms, but the tiotropium arm of
the INHANCE trial was open-label.6 Patient characteristics
in these trials are summarised in Table 1. Each of these
trials provided data on bronchodilatory improvement in
disease status (FEV1 at week 12 was the primary endpoint)
and exacerbations.FEV1 improvement
Transition probabilities used in the model were based on
the proportion of patients who moved from one disease
severity state at baseline to another at week 12. The
transition matrices describing the movement of patients
over the first 12 weeks in the INHANCE and INLIGHT-2 trials
are presented in Table 2.
This transition matrix was applied to the first cycle of
the model only, to describe the initial improvement in FEV1
after starting therapy. As COPD is a degenerative disease,
the patients experience only an initial improvement in their
disease severity at start of therapy. While some patients
continued to improve beyond week 12 in the trial, this is
rare in a clinical setting and as a conservative approach the
decision to confine improvement of disease to the first
cycle (12 weeks) was taken.Exacerbation rates
Exacerbation rates for untreated patients in the model
were based on the placebo control arms of the indacaterol
trials. The trials had similar annual rates ranging from 0.60
to 0.74 exacerbations per patient per year and these rates
set the overall number of exacerbations that occurred in
the model. For the purposes of this model a resource use
based definition of exacerbation was used: severe exacer-
bations required hospitalisation and non-severe required
a change in medication and/or contact with a healthcare
provider. Different distributions were defined for each
disease severity. This was made possible by pooling the
exacerbations from the indacaterol trials and using the
most recent pre-bronchodilator FEV1 value recorded before
an exacerbation to classify the disease severity status in
which the exacerbation took place. The resulting distribu-
tion is shown in Table 3, which shows the frequency of each
type of exacerbation by disease severity.
Rate ratios to describe the treatment effect on exacer-
bations were taken from the respective studies. Rates of
exacerbation per year were low in the clinical trials (typi-
cally around 0.5 per patient for all treatments) since
patients were not recruited on the basis of a history of
exacerbation. All rate ratios were applied to the baseline
rate of exacerbations, and therefore rate ratios versus
placebo were used. Annual exacerbation rates could not be
derived for each treatment by disease severity from the
trial data due to the small number of observed events in
each study.Epidemiology of COPD
Other clinical model inputs were the rate of lung function
decline in COPD patients, mortality data and persistence
data. These were based on sources in the literature or
assumptions. The rate of lung function decline for COPD
patients was derived from the UPLIFT22 trial, which gives
the annual rate of decline in pre-bronchodilator FEV1
measurements as 30 ml per year with a standard error of
1 ml. UPLIFT is the only long-term trial to provide an annual
lung function rate decline for both pre-and post-broncho-
dilator FEV1 values. Two different mortality rates were
Table 2 Transition matrix (baseline to 12 weeks) from the INHANCE and INLIGHT-2 trials.
INHANCE
From
Mild Moderate Severe V. Severe
150 mg indacaterol
To Mild 60.00% 8.22% 0.64% 0.00%
Moderate 40.00% 84.25% 38.85% 2.63%
Severe 0.00% 7.53% 58.60% 63.16%
V. Severe 0.00% 0.00% 1.91% 34.21%
300 mg indacaterol
To Mild 62.50% 15.07% 0.60% 0.00%
Moderate 25.00% 78.77% 38.32% 9.09%
Severe 12.50% 5.48% 58.68% 63.64%
V. Severe 0.00% 0.68% 2.40% 27.27%
18 mg tiotropium
To Mild 60.00% 11.11% 0.52% 0.00%
Moderate 40.00% 84.26% 30.89% 2.33%
Severe 0.00% 4.63% 64.40% 55.81%
V. Severe 0.00% 0.00% 4.19% 41.86%
INLIGHT-2
150 mg indacaterol
To Mild 66.67% 14.29% 0.69% 0.00%
Moderate 33.33% 75.40% 27.59% 0.00%
Severe 0.00% 9.52% 68.97% 57.14%
V. Severe 0.00% 0.79% 2.76% 42.86%
50 mg salmeterol bid
To Mild 75.00% 9.57% 0.00% 0.00%
Moderate 25.00% 80.87% 23.08% 0.00%
Severe 0.00% 9.57% 70.63% 53.85%
V. Severe 0.00% 0.00% 6.29% 46.15%
Cost-utility analysis of indacaterol in Germany 1639obtained in order to fully describe the death rate of a COPD
population. The first was a COPD-related mortality and the
second was an all cause mortality rate used to account for
deaths from competing causes in the study population. The
first was obtained from a published study which gave
mortality rates for a COPD patient cohort and grouped them
by COPD disease severity.23 While this source counts all
cause mortality within this cohort, we have made the
assumption that all deaths recorded within this study were
COPD-related, since separate measures of COPD-
attributable death by disease severity (required to sepa-
rate the types of death) were not available. All cause
mortality was obtained from death tables of the Federal
Statistical Office of Germany24 and used in the model; theseTable 3 Exacerbation severity distribution by disease severity
Combined placebo arm Mild Moderat
Events % Events
Non-severe 3 100% 125
Severe 0 0% 8
Exacerbation events measured over duration of 6 month trials.were not adjusted for estimated COPD-specific deaths due
to lack of data.Economic model inputs
Medical resource use data were obtained from different
sources since the data collected in the clinical trials were
limited and not representative of real world clinical prac-
tice. A combination of German cost sources and the liter-
ature were therefore employed. Table 4 shows the costs for
all healthcare services used in the model, while Table 5
shows annual utilization rates that were applied to these
costs.(pooled data set).
e Severe V. Severe
% Events % Events %
94% 217 92% 48 91%
6% 20 8% 5 9%
Table 4 Costs for health care services used in the model.
Item Cost (in EUR) Source
Maintenance
GP Visit (per consultation) 35.75 EBM code 03112: patient lump
sum (30)
Spirometry 5.96 EBM code 03330: spirometry
(30)
Exacerbations
Hospitalization 2448.44 G-DRG E65B, based on average
base case value for 2010 (25;
32)
Physiotherapist (per hour) 38.52 Physiotherapy code 20702 (29)
(31)
ER Visit 22.87 EBM codes 01210 þ 01211:
Emergency lump sums (30)
Ambulance Transportation to
ER
520.00 Cost for an ambulance without
emergency physician (30)
Drugs (daily cost)
Indacaterol 150 mg 1.44 Lauer-Taxe, weighted averages
Indacaterol 300 mg 2.15
Tiotropium 18 mg 1.81
Salmeterol 2  50 mg 1.63
Influenza vaccination 17.06
Theophylline 0.29
Mucolytics 0.49
Oral Corticosteroids 0.41
SABAs 0.17
Antibioticsa 2.13
Total Costs
Total costs are calculated by multiplying the unit costs of this table with the resource use of Table 5.
Total annual maintenance
Costs
Mild 58.77
Moderate 122.47
Severe 196.13
Very Severe 320.52
Total exacerbation costs
(per episode)
Non-severe exacerbation 63.53
Severe exacerbation 3146.08
a In case of exacerbations (27).
1640 D. Price et al.Drug prices were calculated for each substance as the
average price of various package sizes and doses listed in the
German drug index (Lauer Taxe) from April 29, 2010; these
were weighted by the individual share of each dose combina-
tion in total prescriptions based on prescription data of 2008 as
published by the IMS COPD database. All drugs prescribed
according to this database were taken into account indepen-
dently if the individual dose was approved for COPD. Further-
more, all prices were from the perspective of SHIs, accounting
for general statutorydiscounts and co-payments. Thisway, the
drugcost calculated in themodelwasveryclose to the real cost
for the SHI, as the weighted average costs were based on the
real distribution with regard to doses and pack sizes.
As only limited prescription data were available for
indacaterol, the distribution between the pack sizes was
based on the Foradil distribution (44% 30-day package and
56% 90-day package) (IMS COPD Database Dec 2008). Foradil
uses identical pack sizes as indacaterol with regard to
therapy days, and has been on the market for over 10 years.
All prices presented in Table 4 are given for one daily dose,
according to recommendations for COPD patients in theGerman label. Formucolytics and short actingbeta2-agonists,
the guideline for COPD Disease Management Programs by the
Federal Joint Committee (Gemeinsamer Bundesausschuss; G-
BA) only allows forAcetylcystein, Ambroxol andCarbocistein,
and for Fenoterol, Salbutamol and Terbutalin respectively.25
Hence, only these substances were considered in the calcu-
lation of the price. The yearly cost of oxygen was assumed to
be 511.17 EUR (430 EURþ 19%VAT), based on theannual price
for an oxygen concentrator from the only publicly available
contractbetweena large regional SHI and serviceproviders.26
For the utilization of oxygen, a yearly usage of 3% was
assumed for GOLD III patients and 20% for GOLD IV patients,
based on the OLIN study.27
The cost for the individual services was calculated
according to the associated points from the Einheitlicher
Bewertungsmaßstab (EBM or Uniform Value Scale), a point
scale for health care services in the ambulatory setting that
expresses themonetary value of different services in relation
to each other.28 Since 2009, the point value is predefined, but
can be adapted as part of annual negotiations. In the model,
the number of points were used as from Jan 01, 2010 and then
Table 5 Utilisation rates.
Annual resource utilisation for
maintenance
Per episode resource utilisation for
exacerbations
Mild Moderate Severe Very severe Non-severe Exacerbation Severe Exacerbation
Influenza vaccination (number
of shots)
1 1 1 1
Theophylline (number days per
patient)
0.00 122.06 161.77 159.07
Mucolytics (number days per
patient)
0.00 39.74 48.31 80.60
Oral Corticosteroids(number of
days per patients)
0.00 21.54 23.73 78.48 10.5 10.5
Oxygen (% patients) 0.00 0.00 0.03 0.2
GP Visit (per surgery
consultation)
1 1 2 2 1
Spirometry (number of tests) 1 1 2 2
Antibiotics (number of days per
patient)
11.02 11.02
Paramedic transport to ER 1
ER visit with Admission
(per visit)
1
Non-ICU hospital stay (per stay) 1
Physiotherapist (hours) 3
These rates were obtained from a combination of studies published by Rutten-van Molken et al., Jansson et al. and assumptions and
were validated by a clinician.
Cost-utility analysis of indacaterol in Germany 1641multiplied with the national point value of currently 0.035048
EUR.29 However, the points cannot be accumulated infinitely,
but are capped by the individual Regelleistungsvolumen
(RLV). Any points exceeding this value are graded down (by
25%, 50% or 75%, depending on the amount exceeded). It is not
possible to account for this effect in themodel, therefore the
full point value was assumed. According to the most recent
recommendations of the SHI head association (GKV-Spitzen-
verband), the costs for physiotherapy for COPD patients stage
III or higher are the same as for breathing therapy for patients
withcysticfibrosis.30 The cost for this codewas taken fromthe
Bremen Association of SHI Physicians (Kassena¨rztliche Ver-
einigung), as this was the most recent one publicly available.
To determine the cost of hospitalization in case of an exac-
erbation, the G-DRG E65B (COPDwithout heavy comorbidities
and complications, without rigid bronchoscopy, without
complicated diagnosis, with FEV1 <35% or age <1 year) was
assumed with a relative weight of 0.834 for 2010 multiplied
with the average base case value for 2010 according to the
Federal Association of the General Regional Sickness Funds.
Ambulatory treatment in hospitals is remunerated in the same
way as in an outpatient setting. Therefore, the same costs as
for a regular GP visit apply. The resource use applied to these
services was based on a combination of published studies and
reviewed by a clinician for validity.23,27Utility model inputs
The indacaterol phase III clinical trial program collected
EQ-5D data at selected patient visits. EQ-5D is a stand-
ardised questionnaire used to measure HRQoL as it relatesto health outcomes, and was developed by the EuroQol
Group. In addition to descriptive information on perceived
health status, it gives a single index or utility value that can
be used across all disease areas making it useful as
a measure of health outcomes at a broad level, such as for
national payers conducting health technology assessments.
Whenever an EQ-5D questionnaire was completed at a time
for which a pre-bronchodilator FEV1 value was available,
the EQ-5D score was labelled as describing the corre-
sponding disease severity. This allowed analysis and pooling
of EQ-5D data from all available phase III trials to describe
the HRQoL at the COPD disease severity stages. Few other
papers have described HRQoL by disease severity and those
that have done so have also used pre-bronchodilator
values.31 Values obtained from the indacaterol trial data
and published sources were overall very similar, with the
exception of the Very Severe state. However, the only
paper to report utility value by severity had wide confi-
dence intervals as evidenced by their standard devia-
tions.31 Other published sources which report utility values
for the very severe state alone give ranges between 0.408
and 0.65516,23. This shows that the trial-based utility data
are slightly higher; however, given the benefits of indaca-
terol in keeping patients back from the more severe
disease severity states, a higher utility value for the very
severe state was a conservative approach to describe
indacaterol’s benefits. No utility data were available from
the trials to describe an exacerbation and therefore these
values were based on a published study which measured
the disutility associated with an exacerbation over a set
amount of time. The utility values describing the various
COPD disease states are shown in Table 6.
Table 6 Utility Values.
Health State From trials (CI) From literature (SD)
Mild 0.82 (0.8e0.84) 0.84 (0.15)
Moderate 0.80 (0.79e0.81) 0.73 (0.23)
Severe 0.77 (0.77e0.78) 0.74 (0.25)
Very severe 0.74 (0.74e0.76) 0.52 (0.26)
Non-severe exacerbation 0.01
Severe exacerbation 0.08
1642 D. Price et al.Results
The total incremental costs and QALYs are summarised in
Table 7 along with the ICER. In comparison to tiotropium
and salmeterol, indacaterol 150 mg improved outcomes at
a lower cost leading to a position of dominance.
Patients who have severe COPD may have their indaca-
terol dose increased to 300 mg on medical advice, particu-
larly if they suffer from breathlessness according to the
SmPC. The INHANCE trial included a comparison of inda-
caterol 300 mg against tiotropium. Using these data, the
results of cost-utility analysis show an ICER of V28,301.
Themodel also allowed exacerbations andmortality to be
estimated over the time horizon. In the comparison versus
salmeterol, approximately 10% of patients receiving inda-
caterol had died after 3 years versus 10.5% in patients
receiving salmeterol. Similarly, approximately 10% of
patients in the indacaterol arm were dead by the end of the
time horizon versus 10.4% in the tiotropium arm. Exacerba-
tion rates, which the model also estimates, showed very
similar outcomes between treatments as well with patients
on active treatment experiencing 1 non-severe and 0.1
severe exacerbations over 3 years.Sensitivity analyses
Univariate sensitivity analyses results are commonly sum-
marised in a tornado diagram, as shown in Fig. 2 for indaca-
terol vs tiotropium.Tornadodiagramsgive an indicationof theTable 7 Cost-Utility Results for indacaterol 150 mg vs tiotropiu
Indacaterol
Total costs V 2067
Total QALYs 2.13
Total Lifeyears 2.71
Deaths (% dead at 3
years)
10.0%
ICER
Indacaterol
Total costs V 2043
Total QALYs 2.13
Total Lifeyears 2.71
Deaths (% dead at 3
years)
10.0%
ICER
a Dominant Z less cost, better outcomes.parameters which are particularly important contributors to
the model’s results. Parameters from clinical trial data were
varied within the 95% CIs and all other parameters for which
uncertainty data were not available were varied by a fixed
proportion. Within the PSA, costs were varied according to
a gamma distribution, utilities by a beta distribution and rate
ratios by a log-normal distribution.32 Tornado diagrams are
generally presented when results have an evaluable ICER. In
this case both results are dominant, but univariate analyses
were conducted in both cases and plotted on a tornado
diagram to illustrate the results. The results indicated that in
addition to themodel settings suchas timehorizonofanalysis,
mortality rates associated with very severe COPD and the
assumed benefit of indacaterol in terms of exacerbation
reduction were significant drivers of the results. Mortality
ratesby severityarean importantdriverof resultsbecause the
lung function benefit has the impact of indirectly slowing
down the progression of disease; a characteristic of a more
severe disease state is a higher mortality rate. Mortality rates
of all stages were tested and still not found to impact the
dominant nature of the results. In the comparison with sal-
meterol, the assumed exacerbation benefit also had a signifi-
cant impact on the results and resulted in an evaluable ICERof
roughly V5800. Removing the exacerbation benefit
completely from the analysis did not change the dominant
nature of the results in either comparison. The rest of the
variations changed the magnitude of incremental costs and
QALYs but had no impact on the dominant result. A further
sensitivity analysis was conducted around potential price
changes for comparators. The sensitivity analysis aroundm and salmeterol with a three-year time horizon.
Tiotropium Difference
V 2415 -V348
2.12 0.008
2.70
10.4%
Dominanta
Salmeterol Difference
V 2179 -V136
2.12 0.009
2.70
10.4%
Dominanta
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Figure 2 Tornado Diagram (indacaterol 150 mg vs tiotropium).
Cost-utility analysis of indacaterol in Germany 1643a price change of indacaterolwithin aþ/ 10%margin did not
impact on the dominant results; similar analyses for the
comparator showed that the comparison against tiotropium
still remained dominant while the comparison against salme-
terol resulted in an ICER of approximately V5000. To test
a more extreme change in price for salmeterol, a 30% price
decrease (V1.15) was tested and resulted in an ICER of
approximatelyV30,000. Drug prices are a significant driver of
the results, and it should be kept in mind that price cuts are
a targeted objective of current health policy in Germany.
The PSA recorded the ICER output for each of the 1000
iterations that were stochastically sampled. The results for
both comparisons are plotted on a cost-effectiveness
plane, in which the x-axis represents the incremental
QALYs and the y-axis represents the incremental costs. The
quadrant in which the ICER falls is informative of the cost-
effectiveness of the treatment under evaluation (see
Fig. 3), and the overall proportion of iterations that fall
within each quadrant is a good indication of the robustness
of the estimated ICER (see Table 8). A cost-effectiveness
acceptability curve (Fig. 4) shows that as the majority of
iterations are dominant, the CEAC is nearly flat regardless
of the willingness to pay. The approximately 10% proba-
bility of being in the southwest quadrant (less costs and
benefits) has been excluded from the CEAC and accounts
for the line hovering around the 90% mark, as there is no
guidance on how to judge the acceptability of such ICERs.Model validation
The model results were compared to other studies and
reviewed by an external health economist to validate itsstructure. Comparisons of life expectancy with several
epidemiology sources for COPD patients33,34 as well as
statistics from the US Centers for Disease Control and
Prevention showed that mortality rates in the model were
similar. Model inputs and outputs were also compared with
existing economic evaluations16,23 and found to be
comparable.Discussion
The ICERs produced in this analysis were driven by the
superior performance of indacaterol in improving lung
function (trough FEV1). Within the model, this allowed some
patients to improve their disease severity classification in
the first 12 weeks. The larger the proportion of patients
improving to a milder disease state, the longer it takes, on
average, for that patient cohort to reach the very severe
states of COPD. While the rate of lung function decline
remained unaffected by treatment choice in this model,
there was an indirect mechanism of slowing the progression
of disease by initial improvement in lung function. Table 9
shows the days spent in the different disease severity
states by treatment, indicating that indacaterol patients
spent more time in the mild and moderate states.
The indacaterol studies showed a similar positive trend
between all active treatments in comparison to placebo in
preventing exacerbations and therefore the absolute
difference in exacerbation benefit between treatments was
not significant. Rate ratios from the trials which directly
compare indacaterol to other bronchodilators all contain
1.0 in the confidence interval, thus making the results
statistically non-significant. The univariate sensitivity
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Figure 3 Cost-effectiveness Plane for indacaterol vs tiotropium and salmeterol.
1644 D. Price et al.analyses show that if indacaterol had demonstrated
a significant difference in exacerbation reductions
compared to the other interventions, the ICERs would have
changed such that a smaller rate ratio (fewer exacerba-
tions) would decrease the ICER, and a higher rate ratio
would increase the ICER.
Input values for mortality rates also had a significant
impact on results. Nomortality benefit was assumed with any
treatment, but the differential mortality rates by disease
severity combined with the improvement in lung function,
which indirectly slowsmortality benefit, bestowedan indirect
mortality benefit. This impact was especially pronounced
when varying the mortality rate for the very severe patient
population.
Time horizon was another determinant of cost-
effectiveness. Extending the time horizon from 3 years to
lifetime reduces the ICER considerably. The model assumed
that the FEV1 benefit incurred at the beginning of treat-
ment will not be lost over the course of the lifetime, that is,
the slope of lines describing lung function decline will
remain parallel between treatment groups until discontin-
uation or death. This assumption holds true for studies up
to 3 years duration (e.g. TORCH35) but has not been
demonstrated in life-long studies and was one of the
reasons why the base case focuses on a 3-year time horizon.
This assumption of a sustained benefit had the impact of
keeping patients back in the milder disease states for
longer and the indirect mortality benefit, as discussed
previously, had an even larger impact on the lifetime
scenario since the benefit continues to accumulate over
time, compared to the 3-year time horizon scenario. For
a lifetime time horizon, the mortality rate input for theTable 8 Proportion of iterations that fall within each quadrant
Dominant Needs evaluation
Tiotropium 89.7% 0.0%
Salmeterol 77.8% 13.2%very severe patient group was a more significant driver than
any of the other parameters, followed by treatment benefit
in reducing exacerbations.
In the alternative comparison using the 300 mg dose for
indacaterol compared to tiotropium, the ICER is approxi-
mately V28,000. With no defined threshold in Germany it is
difficult to state explicitly that this is or is not cost-
effective. However, using the UK NICE threshold of
£20,000 to £30,000 as a guide, the indacaterol 300 mg dose
is below the upper level of that range and therefore may be
considered cost-effective.
Incremental results of this analysis showed that the
differences in QALYs across active comparators were small.
These small differences can be attributed to the fact that
the model is driven by disease severity as defined by lung
function, and the bronchodilators are also used to alleviate
symptoms such as cough, breathlessness and dyspnoea.
Changes in these symptoms are difficult to capture as
a change in utility using a non-disease specific measure
such as the EQ-5D. However, the strength of the utility
approach in addition to allowing comparisons across diverse
diseases is that it attempts to capture the full impact of the
disease and treatment benefits as opposed to focusing on
a single outcome, which is important in a multifactorial
disease such as COPD. Difference in total costs between
comparators was also modest.Limitations
In addition to the limitations noted in the rest of the paper,
especially around mortality rates and implicit benefits.
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Figure 4 Cost-effectiveness acceptability curve: indacaterol vs. tiotropium.
Cost-utility analysis of indacaterol in Germany 1645around it, the structure of a Markov model makes it
impossible to keep track of patients who discontinue. This
would be necessary to adjust their FEV1 values to reflect
the fact that they had discontinued treatment. However,
since discontinuation rates are assumed equal across
bronchodilators the impact was minimal. Indacaterol trial
patient disposition data showed that discontinuation rates
were similar among all three interventions. Discontinuation
rates were only a driver if different rates could be assumed
for different comparators.
It should also be noted that there is currently little
evidence which clarifies the relationship between change in
lung function and health status change. In this model,
change in health status benefit is due to change in disease
severity level, which is driven by lung function.
Furthermore, it should be noted that this analysis is
based on direct clinical trial data and as such, external
applicability of the results is limited. The ideal analysis
would be based entirely on real world evidence; however,
this is currently not available. Key areas of this limitation
include comorbidities, the use of inaccurate DRGs toTable 9 Time (days) spent in each model state (over 3 years).
Indacaterol 150 mg vs. Tiotropium 18
(based on INHANCE trial)
Indacaterol Tiotropiu
Mild 43 53
Moderate 515 475
Severe 412 420
V. Severe 65 84
Death 60 62describe the SHI perspective and extrapolation of the
clinical data. These are discussed in detail in the rest of this
section. A key topic for future research would be the vali-
dation of these points against real world evidence as and
when it becomes available.
In common with most RCTs, patients were excluded if
they had comorbidities that would put them at risk, or
would prevent the interpretation of safety or efficacy data.
This meant that anyone with an unstable comorbidity was
excluded, although many ‘stable’ co-morbities (e.g., type 2
diabetes mellitus and high blood pressure) were permitted
entry into the studies. In the absence of ‘real world’ data,
costs attributable to comorbidities are excluded from the
analysis. However, since this applies to all treatment arms
the exclusion should not significantly change the ICER
(although it could lower the total costs of treating COPD
patients).
The use of an SHI perspective may underestimate the
‘true cost’ of treatment within the healthcare system, as it
does not take into account the opportunity costs of physi-
cians/hospitals who have increased resource use but cannotmg Indacaterol 150 mg vs. Salmeterol 50 mg
bid (based on INLIGHT2 trial)
m Indacaterol Salmeterol
72 49
456 454
440 446
68 84
59 62
1646 D. Price et al.claim higher fees from the SHI. This is a common problem
with every evaluation within a fixed-rate system. However,
the analysis is an accurate representation of costs incurred
by the SHI.
The clinical data used in this model were derived from
trials of six months duration and therefore a limitation of the
analysis is the uncertainty introduced in projecting these
data to the 3 year base case period and a lifetime (20 years)
horizon. Lung function improvement at 12 weeks was the
primary measure which was only applied in the first cycle of
the model but evidence of the sustainability of this benefit,
beyond 3 years is not available. When observational studies
covering longer durations become available it may be
possible to validate the model’s long-term projections. It is
also arguable that clinical studies of 6 months duration are
not sufficiently long to capture seasonal variation with
regard to exacerbation rates and therefore amodel based on
these may not be genarilzable to the real world. However
recruitment in these studies was spread out such that the
total observation period spanned more than 6 months and
was conducted in both the northern and southern hemi-
spheres. As exacerbationswerenot aprimaryor keyendpoint
of these studies, and thus patients were not recruited with
this in mind, the overall rate of exacerbations observed was
very low.Thiswas not the ideal data source for exacerbations
but the best data to describe the exacerbation benefits of
indacaterol currently available. To test the uncertainty of
the clinical evidence, these parameters are included in the
univariate and probabilistic sensitivity analyses. Given the
very low and very similar rates of exacerbation between the
comparators, disabling the exacerbation parameters had
very little impact on the results.
Conclusion
The cost-utility analyses of indacaterol compared to tio-
tropium and salmeterol used in maintenance treatment of
COPD in Germany showed that indacaterol dominates in both
comparisons and is likely to remain cost-effective under
a range of assumptions. The comparison using a 300 mg dose
with tiotropium shows that the higher dose form is still well-
positioned to demonstrate cost-effectiveness.
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